Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Patrick Johnston to Adult

This is a "connection" page, showing publications Patrick Johnston has written about Adult.

 
Connection Strength
 
 
 
1.030
 
  1. Lowe BG, Yamamoto N, Robinson J, Johnston P. The latency of a domain-general visual surprise signal is attribute dependent. Cortex. 2026 Jan; 194:96-106.
    View in: PubMed
    Score: 0.047
  2. Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Transplant Cell Ther. 2024 10; 30(10):1001.e1-1001.e12.
    View in: PubMed
    Score: 0.042
  3. Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024 07 01; 109(7):2186-2195.
    View in: PubMed
    Score: 0.042
  4. Lowe BG, Robinson JE, Yamamoto N, Hogendoorn H, Johnston P. Same but different: The latency of a shared expectation signal interacts with stimulus attributes. Cortex. 2023 Nov; 168:143-156.
    View in: PubMed
    Score: 0.040
  5. Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022 09; 28(9):610-617.
    View in: PubMed
    Score: 0.037
  6. Baker KS, Pegna AJ, Yamamoto N, Johnston P. Attention and prediction modulations in expected and unexpected visuospatial trajectories. PLoS One. 2021; 16(10):e0242753.
    View in: PubMed
    Score: 0.035
  7. Barreto JN, Bansal R, Hathcock MA, Doleski CJ, Hayne JR, Truong TA, Nedved AN, Ansell SM, Bennani NN, Paludo J, Villasboas JC, Lin Y, Johnston PB. The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T-cell therapy. Am J Hematol. 2021 10 01; 96(10):E399-E402.
    View in: PubMed
    Score: 0.035
  8. Johnston P, Robinson J, Kokkinakis A, Ridgeway S, Simpson M, Johnson S, Kaufman J, Young AW. Temporal and spatial localization of prediction-error signals in the visual brain. Biol Psychol. 2017 04; 125:45-57.
    View in: PubMed
    Score: 0.025
  9. Wang J, Pulido JS, O'Neill BP, Johnston PB. Second malignancies in patients with primary central nervous system lymphoma. Neuro Oncol. 2015 Jan; 17(1):129-35.
    View in: PubMed
    Score: 0.021
  10. Rollins KE, Ollivere BJ, Johnston P. Predicting successful outcomes of wrist and finger Ganglia. Hand Surg. 2013; 18(1):41-4.
    View in: PubMed
    Score: 0.019
  11. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May; 85(5):320-4.
    View in: PubMed
    Score: 0.016
  12. Williams MA, McGimpsey S, Abugreen S, Chan W, Sharkey JA, Best RM, Johnston PB. The incidence and rate of rhegmatogenous retinal detachment seven years after cataract surgery in patients with high myopia. Ulster Med J. 2009 May; 78(2):99-104.
    View in: PubMed
    Score: 0.015
  13. Advani RH, Kelsey CR, Armand P, Bello CM, Benitez CM, Bond D, Chen W, Cherian S, Czader M, Dabaja B, Daly ME, Frosch Z, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Hoppe RT, Isufi I, Johnston PB, Kelly K, Kenkre VP, Kline J, Lynch RC, McConathy J, Morgan D, Niu A, Paul S, Rabinovitch R, Salavati A, Sano D, Shah H, Spinner M, Svoboda J, Winter JN, Yahalom J, Yang JC, Montgomery S, Stehman K. Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Feb; 24(2):41-60.
    View in: PubMed
    Score: 0.012
  14. Mondello P, Negaard B, Feldman AL, Link BK, Casulo C, Chihara D, Russler-Germain D, Romancik J, Gribbin C, Haddadi S, Mou E, Micallef IN, Johnston PB, Novak J, Wang Y, King RL, Novak AJ, Habermann TM, Martin P, Kahl B, Nowakowski GS, Nastoupil LJ, Cerhan JR, Flowers CR, Lossos IS, Burack RW, Maurer MJ, Ansell SM. Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohorts. Blood Cancer J. 2025 Aug 08; 15(1):134.
    View in: PubMed
    Score: 0.011
  15. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Chow VA, Montheard S, Santamaria J, Colicino S, Ogasawara K, Stepan L, Liu FF, Abramson JS. Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. J Clin Oncol. 2025 Aug 20; 43(24):2671-2678.
    View in: PubMed
    Score: 0.011
  16. Assouline SE, Mehta A, Hanel W, Doucet S, Johnston PB, Danilov A, Cooper BW, Chudnovsky A, Ding J, Long T, Stroopinsky D, Berg D, Alinari L. Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2025 Nov; 25(11):788-799.e11.
    View in: PubMed
    Score: 0.011
  17. Hwang SR, Godby RC, Negaard BJ, Mwangi R, Nedved AN, Barreto JN, Micallef IN, Ansell SM, Porrata L, Durani U, Thanarajasingam G, Habermann TM, Maurer MJ, Johnston PB, Khurana A. Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experience. Blood Adv. 2025 Feb 25; 9(4):924-932.
    View in: PubMed
    Score: 0.011
  18. Van Pelt J, Lowe BG, Robinson JE, Donaldson MJ, Johnston P, Yamamoto N. An event-related potential study of onset primacy in visual change detection. Atten Percept Psychophys. 2025 May; 87(4):1219-1229.
    View in: PubMed
    Score: 0.011
  19. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Alhaj Moustafa M, Murthy HS, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy. Blood Adv. 2024 09 24; 8(18):4877-4885.
    View in: PubMed
    Score: 0.011
  20. Skolka MP, Suanprasert N, Martinez-Thompson JM, King RL, Macon WR, Mauermann ML, Klein CJ, Habermann TM, Johnston PB, Micallef IN, Khurana A, Amrami K, Spinner RJ, Mandrekar J, Dyck PJ, Dyck PJB. Neurologic Clinical, Electrophysiologic, and Pathologic Characteristics of Primary vs Secondary Neurolymphomatosis. Neurology. 2024 Sep 24; 103(6):e209777.
    View in: PubMed
    Score: 0.011
  21. Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, Paludo J, Villasboas JC, Dingli D, Kourelis T, Leung N, Alkhateeb H, Ruff MW, Gallo de Moraes A, Vergidis P, Herrmann J, Kenderian SS, Bennani NN, Johnston PB, Ansell SM, Lin Y. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. Blood Cancer J. 2024 08 12; 14(1):136.
    View in: PubMed
    Score: 0.011
  22. Okcu I, Wang Y, Bock AM, Zhou J, Moustafa MA, Tun HW, Rosenthal AC, Johnston PB, Baidoun F, Khurana A, Kabat BF, King RL, Habermann TM, Nowakowski GS. Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clin Lymphoma Myeloma Leuk. 2025 Feb; 25(2):116-123.
    View in: PubMed
    Score: 0.011
  23. Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Crotta A, Montheard S, Previtali A, Ogasawara K, Kamdar M. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023 04 06; 141(14):1675-1684.
    View in: PubMed
    Score: 0.010
  24. Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason J, Glass B, Mutsaers P, Lunning M, Braverman J, Liu FF, Crotta A, Montheard S, Previtali A, Guo S, Shi L, Solomon SR. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022 12 13; 6(23):5969-5979.
    View in: PubMed
    Score: 0.010
  25. McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, Bennani N, Thanarajasingam G, Nowakowski G, Porrata L, Thompson C, Micallef I, Johnston P, Ansell S, Paludo J. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023 02; 64(2):371-377.
    View in: PubMed
    Score: 0.009
  26. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2023 Jan; 10(1):e14-e23.
    View in: PubMed
    Score: 0.009
  27. Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers P, Hernandez-Ilizaliturri F, Izutsu K, Morschhauser F, Lunning M, Maloney DG, Crotta A, Montheard S, Previtali A, Stepan L, Ogasawara K, Mack T, Abramson JS. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022 06 18; 399(10343):2294-2308.
    View in: PubMed
    Score: 0.009
  28. Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022 03; 196(5):1209-1218.
    View in: PubMed
    Score: 0.009
  29. Desai SH, LaPlant B, Macon WR, King RL, Wang Y, Inwards DJ, Micallef I, Johnston PB, Porrata LF, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer J. 2021 09 25; 11(9):160.
    View in: PubMed
    Score: 0.009
  30. Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Braksick SA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. Am J Hematol. 2021 11 01; 96(11):E427-E430.
    View in: PubMed
    Score: 0.009
  31. Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer J. 2021 07 01; 11(7):124.
    View in: PubMed
    Score: 0.009
  32. Melody M, Gandhi S, Rahman ZA, Lengerke-Diaz P, Gannon N, Rosenthal A, Truong T, Novo M, Brandes E, Lange G, Estby B, Johnston P, Ansell S, Bennani NN, Paludo J, Bisneto JV, Ayala E, Tun HW, Murthy HS, Roy V, Foran J, Castro J, Lin Y, Kharfan-Dabaja MA. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. Eur J Haematol. 2021 Jul; 107(1):48-53.
    View in: PubMed
    Score: 0.008
  33. Gile JJ, Lopez CL, Ruan GJ, Hathcock MA, Abeykoon JP, Heimgartner JR, Baumann NA, McMahon MM, Micallef IN, Johnston PB, Bisneto JCV, Porrata LF, Paludo J, Ansell SM, Hogan WJ, Witzig TE. Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. Blood Cancer J. 2021 03 26; 11(3):65.
    View in: PubMed
    Score: 0.008
  34. Higgins A, Kim H, Harper L, Habermann TM, Nowakowski GS, Thompson CA, Johnston P, Witzig TE, Allmer C, Maurer MJ, Cerhan JR, Young JR, Thanarajasingam G. Testicular FDG-PET/CT uptake threshold in aggressive lymphomas. Am J Hematol. 2021 03 01; 96(3):E81-E83.
    View in: PubMed
    Score: 0.008
  35. Kitamura H, Johnston P, Johnson L, Strodl E. Boundary conditions of post-retrieval extinction: A direct comparison of low and high partial reinforcement. Neurobiol Learn Mem. 2020 10; 174:107285.
    View in: PubMed
    Score: 0.008
  36. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Bierman PJ, Boughan KM, Dabaja B, Gordon LI, Hernandez-Ilizaliturri FJ, Herrera AF, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, McKinney M, Metzger M, Morgan D, Mulroney C, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Winter JN, Yahalom J, Burns JL, Ogba N. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 06; 18(6):755-781.
    View in: PubMed
    Score: 0.008
  37. Novek J, Bettess S, Burke K, Johnston P. Nurses' perceptions of the reliability of an automated medication dispensing system. J Nurs Care Qual. 2000 Jan; 14(2):1-13.
    View in: PubMed
    Score: 0.008
  38. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2020 03; 95(3):274-281.
    View in: PubMed
    Score: 0.008
  39. Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood. 2019 09 12; 134(11):851-859.
    View in: PubMed
    Score: 0.008
  40. Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, Nowakowski GS. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol. 2019 07 20; 37(21):1819-1827.
    View in: PubMed
    Score: 0.007
  41. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Villasboas JC, Markovic SN. Autograft immune content and survival in non-Hodgkin's lymphoma: A post hoc analysis. Leuk Res. 2019 06; 81:1-9.
    View in: PubMed
    Score: 0.007
  42. Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, Macon WR, Micallef INM, King RL, Salomao DR, Witzig TE, Habermann TM, Nowakowski GS. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. Am J Hematol. 2019 03; 94(3):291-298.
    View in: PubMed
    Score: 0.007
  43. Durojaiye OC, Kritsotakis EI, Johnston P, Kenny T, Ntziora F, Cartwright K. Developing a risk prediction model for 30-day unplanned hospitalization in patients receiving outpatient parenteral antimicrobial therapy. Clin Microbiol Infect. 2019 Jul; 25(7):905.e1-905.e7.
    View in: PubMed
    Score: 0.007
  44. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P. Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. Leukemia. 2019 03; 33(3):790-794.
    View in: PubMed
    Score: 0.007
  45. Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR. History of autoimmune conditions and lymphoma prognosis. Blood Cancer J. 2018 08 01; 8(8):73.
    View in: PubMed
    Score: 0.007
  46. Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 10; 18(10):664-672.e2.
    View in: PubMed
    Score: 0.007
  47. Phillips TJ, Forero-Torres A, Sher T, Diefenbach CS, Johnston P, Talpaz M, Pulini J, Zhou L, Scherle P, Chen X, Barr PM. Phase 1 study of the PI3Kd inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma. Blood. 2018 07 19; 132(3):293-306.
    View in: PubMed
    Score: 0.007
  48. Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol. 2018 06 01; 36(16):1603-1610.
    View in: PubMed
    Score: 0.007
  49. Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, Thompson CA, Farooq U, Novak AJ, Slager SL, Allmer C, Lunde JJ, Macon WR, Inwards DJ, Johnston PB, Micallef INM, Nowakowski GS, Ansell SM, Kay NE, Weiner GJ, Witzig TE. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. Int J Epidemiol. 2017 12 01; 46(6):1753-1754i.
    View in: PubMed
    Score: 0.007
  50. Kansagra A, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN, Porrata LF. Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation. Bone Marrow Transplant. 2018 02; 53(2):146-154.
    View in: PubMed
    Score: 0.007
  51. Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol. 2018 10; 183(1):149-152.
    View in: PubMed
    Score: 0.007
  52. Dispenzieri A, D'Souza A, Gertz MA, Laumann K, Wiseman G, Lacy MQ, LaPlant B, Buadi F, Hayman SR, Kumar SK, Dingli D, Hogan WJ, Ansell SM, Gastineau DA, Inwards DJ, Micallef IN, Porrata LF, Johnston PB, Litzow MR, Witzig TE. A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma. Bone Marrow Transplant. 2017 Oct; 52(10):1372-1377.
    View in: PubMed
    Score: 0.007
  53. Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Johnston PB, Micallef IN, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J. 2017 08 25; 7(8):e595.
    View in: PubMed
    Score: 0.007
  54. Murphy CM, Christakou A, Giampietro V, Brammer M, Daly EM, Ecker C, Johnston P, Spain D, Robertson DM, Murphy DG, Rubia K. Abnormal functional activation and maturation of ventromedial prefrontal cortex and cerebellum during temporal discounting in autism spectrum disorder. Hum Brain Mapp. 2017 11; 38(11):5343-5355.
    View in: PubMed
    Score: 0.007
  55. Greenwood LM, Leung S, Michie PT, Green A, Nathan PJ, Fitzgerald P, Johnston P, Solowij N, Kulkarni J, Croft RJ. The effects of glycine on auditory mismatch negativity in schizophrenia. Schizophr Res. 2018 01; 191:61-69.
    View in: PubMed
    Score: 0.006
  56. Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. Br J Haematol. 2017 08; 178(3):427-433.
    View in: PubMed
    Score: 0.006
  57. Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92(5):448-453.
    View in: PubMed
    Score: 0.006
  58. Bixby SD, Jarrett DY, Johnston P, Mahan ST, Kleinman PK. Posteromedial subtalar coalitions: prevalence and associated morphological alterations of the sustentaculum tali. Pediatr Radiol. 2016 Jul; 46(8):1142-9.
    View in: PubMed
    Score: 0.006
  59. Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood. 2016 Apr 21; 127(16):1960-6.
    View in: PubMed
    Score: 0.006
  60. Neale C, Johnston P, Hughes M, Scholey A. Functional Activation during the Rapid Visual Information Processing Task in a Middle Aged Cohort: An fMRI Study. PLoS One. 2015; 10(10):e0138994.
    View in: PubMed
    Score: 0.006
  61. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Infused autograft lymphocyte-to-monocyte ratio and survival in T-cell lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation. J Hematol Oncol. 2015 Jul 03; 8:80.
    View in: PubMed
    Score: 0.006
  62. Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, Gupta M. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015 Jul 16; 126(3):328-35.
    View in: PubMed
    Score: 0.006
  63. Cadman T, Spain D, Johnston P, Russell A, Mataix-Cols D, Craig M, Deeley Q, Robertson D, Murphy C, Gillan N, Wilson CE, Mendez M, Ecker C, Daly E, Findon J, Glaser K, Happé F, Murphy D. Obsessive-Compulsive Disorder in Adults with High-Functioning Autism Spectrum Disorder: What Does Self-Report with the OCI-R Tell Us? Autism Res. 2015 Oct; 8(5):477-85.
    View in: PubMed
    Score: 0.006
  64. Johnston PB, Lotery AJ, Logan WC. Treatment and long-term follow up of a capillary angioma of the optic disc. Int Ophthalmol. 1995; 19(2):129-32.
    View in: PubMed
    Score: 0.005
  65. Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clément C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, Nowakowski GS, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014 Nov 01; 32(31):3506-12.
    View in: PubMed
    Score: 0.005
  66. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015 Jan 20; 33(3):251-7.
    View in: PubMed
    Score: 0.005
  67. Oki Y, Buglio D, Zhang J, Ying Y, Zhou S, Sureda A, Ben-Yehuda D, Zinzani PL, Prince HM, Harrison SJ, Kirschbaum M, Johnston PB, Shen A, von Tresckow B, Younes A. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J. 2014 Aug 08; 4:e236.
    View in: PubMed
    Score: 0.005
  68. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. Infused autograft lymphocyte to monocyte ratio and survival in diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1804-12.
    View in: PubMed
    Score: 0.005
  69. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Dec; 55(12):2728-38.
    View in: PubMed
    Score: 0.005
  70. Wang M, Popplewell LL, Collins RH, Winter JN, Goy A, Kaminski MS, Bartlett NL, Johnston PB, Lister J, Fanning SR, Tuscano JM, Beck JT, Kaya H, Robeva A, Fan J, Klimovsky J, Cheung W, Cherfi A, O'Connor OA. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014 May; 165(4):510-8.
    View in: PubMed
    Score: 0.005
  71. Karam C, Mauermann ML, Johnston PB, Lahoria R, Engelstad JK, Dyck PJ. Immune-mediated neuropathies following stem cell transplantation. J Neurol Neurosurg Psychiatry. 2014 Jun; 85(6):638-42.
    View in: PubMed
    Score: 0.005
  72. Salomão DR, Pulido JS, Johnston PB, Canal-Fontcuberta I, Feldman AL. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma. JAMA Ophthalmol. 2013 Sep; 131(9):1151-8.
    View in: PubMed
    Score: 0.005
  73. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013 Sep 10; 31(26):3272-8.
    View in: PubMed
    Score: 0.005
  74. Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol. 2013 Jul; 88(7):589-93.
    View in: PubMed
    Score: 0.005
  75. Singla A, Hogan WJ, Ansell SM, Buadi FK, Dingli D, Dispenzieri A, Gastineau DA, Gertz MA, Hayman SR, Inwards DJ, Johnston PB, Lacy MQ, Litzow MR, Micallef IN, Porrata LF, Kumar SK. Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2013 Aug; 19(8):1233-7.
    View in: PubMed
    Score: 0.005
  76. Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE. Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol. 2013 Sep; 24(9):2439-43.
    View in: PubMed
    Score: 0.005
  77. Dispenzieri A, Seenithamby K, Lacy MQ, Kumar SK, Buadi FK, Hayman SR, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Johnston PB, Porrata LF, Patnaik MM, Hogan WJ, Gertz MA. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant. 2013 Oct; 48(10):1302-7.
    View in: PubMed
    Score: 0.005
  78. Silvestri G, Archer DB, Johnston PB. Peripapillary subretinal neovascular membranes: the natural history. Eye (Lond). 1993; 7 ( Pt 3):398-402.
    View in: PubMed
    Score: 0.005
  79. Micallef IN, Sinha S, Gastineau DA, Wolf R, Inwards DJ, Gertz MA, Hayman SR, Hogan WJ, Johnston PB, Lacy MQ, Ansell SM, Buadi F, Dingli D, Dispenzieri A, Litzow MR, Porrata LF, Winters JL, Kumar S. Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant. 2013 Jan; 19(1):87-93.
    View in: PubMed
    Score: 0.005
  80. Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, Macon W, Colgan JP, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012 Nov; 53(11):2159-65.
    View in: PubMed
    Score: 0.005
  81. D'Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S, Dingli D, Zeldenrust S, Kyle R, Ansell S, Inwards D, Johnston P, Micallef I, Porrata L, Litzow M, Gastineau D, Hogan W, Dispenzieri A. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood. 2012 Jul 05; 120(1):56-62.
    View in: PubMed
    Score: 0.005
  82. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong TC, Prince HM, Harrison SJ, Kirschbaum M, Johnston P, Gallagher J, Le Corre C, Shen A, Engert A. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012 Jun 20; 30(18):2197-203.
    View in: PubMed
    Score: 0.005
  83. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012 May; 157(3):321-30.
    View in: PubMed
    Score: 0.005
  84. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012 Apr; 53(4):575-80.
    View in: PubMed
    Score: 0.004
  85. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012 Feb; 97(2):262-9.
    View in: PubMed
    Score: 0.004
  86. Sellar PW, Johnston PB. Ocular injuries due to exploding bottles of carbonated drinks. BMJ. 1991 Jul 20; 303(6795):176-7.
    View in: PubMed
    Score: 0.004
  87. Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011 Dec; 25(12):1877-81.
    View in: PubMed
    Score: 0.004
  88. Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011 Nov 03; 118(18):4882-9.
    View in: PubMed
    Score: 0.004
  89. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011 Sep; 25(9):1502-9.
    View in: PubMed
    Score: 0.004
  90. Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Porrata LF, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, Syrbu SI, Kurtin PJ, Macon WR, Nikcevich DA, Witzig TE. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011 Apr 20; 29(12):1620-6.
    View in: PubMed
    Score: 0.004
  91. Johnston PB. Traumatic retinal detachment. Br J Ophthalmol. 1991 Jan; 75(1):18-21.
    View in: PubMed
    Score: 0.004
  92. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25(2):341-7.
    View in: PubMed
    Score: 0.004
  93. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, Kelly JL, Macon WR, Nowakowski GS, Inwards DJ, Johnston PB, Singh RJ, Allmer C, Slager SL, Weiner GJ, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol. 2010 Sep 20; 28(27):4191-8.
    View in: PubMed
    Score: 0.004
  94. Ecker C, Marquand A, Mourão-Miranda J, Johnston P, Daly EM, Brammer MJ, Maltezos S, Murphy CM, Robertson D, Williams SC, Murphy DG. Describing the brain in autism in five dimensions--magnetic resonance imaging-assisted diagnosis of autism spectrum disorder using a multiparameter classification approach. J Neurosci. 2010 Aug 11; 30(32):10612-23.
    View in: PubMed
    Score: 0.004
  95. Dispenzieri A, Wiseman GA, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Laumann KM, Allred J, Geyer SM, Litzow MR, Gastineau DA, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Johnston PB, Hogan WJ, Gertz MA. A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma. Am J Hematol. 2010 Jun; 85(6):409-13.
    View in: PubMed
    Score: 0.004
  96. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, Thompson CA, Markovic SN. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia. 2010 Jul; 24(7):1343-9.
    View in: PubMed
    Score: 0.004
  97. Naina HV, Pruthi RK, Inwards DJ, Dingli D, Litzow MR, Ansell SM, William HJ, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Gertz MA, Hayman SR, Johnston PB, Lacy MQ, Micallef IN, Porrata LF, Kumar S. Low risk of symptomatic venous thromboembolic events during growth factor administration for PBSC mobilization. Bone Marrow Transplant. 2011 Feb; 46(2):291-3.
    View in: PubMed
    Score: 0.004
  98. Porrata LF, Inwards DJ, Micallef IN, Johnston PB, Ansell SM, Hogan WJ, Markovic SN. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin Dev Immunol. 2010; 2010:914945.
    View in: PubMed
    Score: 0.004
  99. Holtan SG, Hogan WJ, Elliott MA, Ansell SM, Inwards DJ, Porrata LF, Johnston PB, Micallef IN, Lacy MQ, Gastineau DA, Litzow MR. CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Transplant. 2010 Dec; 45(12):1699-703.
    View in: PubMed
    Score: 0.004
  100. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 01; 115(13):2578-85.
    View in: PubMed
    Score: 0.004
  101. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Hogan WJ, Markovic SN. New-onset lymphopenia assessed during routine follow-up is a risk factor for relapse postautologous peripheral blood hematopoietic stem cell transplantation in patients with diffuse large B-cell lymphoma. Biol Blood Marrow Transplant. 2010 Mar; 16(3):376-83.
    View in: PubMed
    Score: 0.004
  102. Karantanis D, Durski JM, Lowe VJ, Nathan MA, Mullan BP, Georgiou E, Johnston PB, Wiseman GA. 18F-FDG PET and PET/CT in Burkitt's lymphoma. Eur J Radiol. 2010 Jul; 75(1):e68-73.
    View in: PubMed
    Score: 0.004
  103. Ecker C, Stahl D, Daly E, Johnston P, Thomson A, Murphy DG. Is there a common underlying mechanism for age-related decline in cortical thickness? Neuroreport. 2009 Aug 26; 20(13):1155-60.
    View in: PubMed
    Score: 0.004
  104. McGalliard JN, Johnston PB. A study of iris melanoma in Northern Ireland. Br J Ophthalmol. 1989 Aug; 73(8):591-5.
    View in: PubMed
    Score: 0.004
  105. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Litzow MR, Ansell SM. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol. 2008 Oct; 143(2):268-73.
    View in: PubMed
    Score: 0.004
  106. Cady FM, O'Neill BP, Law ME, Decker PA, Kurtz DM, Giannini C, Porter AB, Kurtin PJ, Johnston PB, Dogan A, Remstein ED. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol. 2008 Oct 10; 26(29):4814-9.
    View in: PubMed
    Score: 0.004
  107. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Litzow MR, Winters JL, Markovic SN. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant. 2008 Jul; 14(7):807-16.
    View in: PubMed
    Score: 0.003
  108. Costa LJ, Feldman AL, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM. Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. Br J Haematol. 2008 Jul; 142(3):404-12.
    View in: PubMed
    Score: 0.003
  109. Costa LJ, Micallef IN, Inwards DJ, Johnston PB, Porrata LF, Ansell SM. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2008 Apr; 41(8):715-20.
    View in: PubMed
    Score: 0.003
  110. Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston PB, Patel R. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008 Feb; 41(4):385-92.
    View in: PubMed
    Score: 0.003
  111. Doolittle ND, Abrey LE, Shenkier TN, Tali S, Bromberg JE, Neuwelt EA, Soussain C, Jahnke K, Johnston P, Illerhaus G, Schiff D, Batchelor T, Montoto S, Kraemer DF, Zucca E. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008 Feb 01; 111(3):1085-93.
    View in: PubMed
    Score: 0.003
  112. Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, Johnston PB, Markovic SN, Micallef IN, Porrata LF, Witzig TE. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma. 2007 Jul; 48(7):1332-7.
    View in: PubMed
    Score: 0.003
  113. Porrata LF, Ristow K, Witzig TE, Tuinistra N, Habermann TM, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Markovic SN. Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia. 2007 Dec; 21(12):2554-6.
    View in: PubMed
    Score: 0.003
  114. Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Porrata LF. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007 Jun; 137(5):409-15.
    View in: PubMed
    Score: 0.003
  115. Holtan SG, Porrata LF, Micallef IN, Padley DJ, Inwards DJ, Ansell SA, Johnston PB, Gastineau DA, Markovic SN. AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. Clin Lymphoma Myeloma. 2007 Jan; 7(4):315-8.
    View in: PubMed
    Score: 0.003
  116. Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, Lewis JT, Markovic SN, Porrata LF, White WL, Witzig TE, Ristow K, Habermann TM. The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma. 2006 Sep; 47(9):1794-9.
    View in: PubMed
    Score: 0.003
  117. Holtan SG, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Litzow MR, Gastineau DA, Markovic SN. Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma. Br J Haematol. 2006 Jun; 133(6):628-33.
    View in: PubMed
    Score: 0.003
  118. Johnston PB, Armstrong MF. Eye injuries in Northern Ireland two years after seat belt legislation. Br J Ophthalmol. 1986 Jun; 70(6):460-2.
    View in: PubMed
    Score: 0.003
  119. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, Kumar SK, Clark R, Kyle RA, Litzow MR, Inwards DJ, Ansell SM, Micallef IM, Porrata LF, Elliott MA, Johnston PB, Greipp PR, Witzig TE, Zeldenrust SR, Russell SJ, Gastineau D, Gertz MA. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006 Apr 15; 107(8):3378-83.
    View in: PubMed
    Score: 0.003
  120. Johnston PB, Maguire CJ, Logan WC. Management of superior-half-bullous retinal detachment. Br J Ophthalmol. 1981 Sep; 65(9):618-22.
    View in: PubMed
    Score: 0.002
  121. Mulholland DA, Johnston PB, Sharkey JA. Pars plana vitrectomy in von Hippel Lindau disease. Eye (Lond). 1996; 10 ( Pt 6):758-9.
    View in: PubMed
    Score: 0.001
  122. Digre KB, Smoker WR, Johnston P, Tryhus MR, Thompson HS, Cox TA, Yuh WT. Selective MR imaging approach for evaluation of patients with Horner's syndrome. AJNR Am J Neuroradiol. 1992 Jan-Feb; 13(1):223-7.
    View in: PubMed
    Score: 0.001
  123. Kidd MN, Lyness RW, Patterson CC, Johnston PB, Archer DB. Prognostic factors in malignant melanoma of the choroid: a retrospective survey of cases occurring in Northern Ireland between 1965 and 1980. Trans Ophthalmol Soc U K (1962). 1986; 105 ( Pt 1):114-21.
    View in: PubMed
    Score: 0.001
  124. Kennedy L, Beacom R, Archer DB, Carson DJ, Campbell SL, Johnston PB, Maguire CJ. Limited joint mobility in Type I diabetes mellitus. Postgrad Med J. 1982 Aug; 58(682):481-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)